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Abstract
Background:  The  success  rates  of  therapies  for  treating  Helicobacter  pylori  vary  greatly  world-
wide and  the  ideal  treatment  has  yet  to  be  clearly  established.
Aims:  A  systematic  review  was  carried  out  to  evaluate  the  effectiveness  of  current  ﬁrst  and
second-line  therapies  in  treating  H.  pylori  infection.
Methods:  Two  researchers  independently  carried  out  Internet  search  engine  reviews  (PUBMED,
EMBASE, MEDLINE)  of  clinical  trials  on  adults  published  between  1990  and  2012  in  both  English
and Spanish.
Results:  Forty-three  (n  =  8,123)  clinical  trials  were  evaluated  that  included  ﬁrst  and  second-line
triple, quadruple,  and  sequential  therapies.  The  eradication  rates  of  the  standard  triple  ther-
apy are  unacceptable  (≤  80%)  in  countries  where  H.  pylori  is  highly  resistant  to  clarithromycin
and metronidazole.  Administration  of  the  standard  triple  therapy  for  more  than  7  days  does
not improve  its  effectiveness.  No  statistically  signiﬁcant  differences  were  observed  between
the eradication  rates  of  the  quadruple  therapy  with  bismuth  and  the  standard  triple  therapy.
Even though  the  sequential  and  concomitant  therapies  are  equally  successful  regimens,  the
triple therapy  with  levoﬂoxacin  offers  the  best  results  as  ﬁrst  and  second-line  treatment,  but
quinolone  resistance  can  diminish  its  effectiveness.  The  triple  therapy  with  levoﬂoxacin  and
the sequential  and  concomitant  treatments  were  superior  to  the  standard  triple  regimen  as
ﬁrst-line  therapy.
Conclusions:  Currently  there  is  no  ideal  ﬁrst  or  second-line  treatment  for  achieving  100%  eradi-
cation. The  therapeutic  order  should  be  carried  out  according  to  the  initial  treatment  and  local
antimicrobial  resistance  studies.
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Tratamiento  ideal  del  Helicobacter  pylori:  una  revisión  sistemática
Resumen
Antecedentes:  Las  tasas  de  éxito  de  las  terapias  para  tratar  el  Helicobacter  pylori  varían
ampliamente  a  nivel  mundial.  El  tratamiento  óptimo  no  ha  sido  claramente  establecido.
Objetivo:  Se  realizó  un  revisión  sistemática  para  evaluar  la  eﬁcacia  de  las  terapias  actuales  de
primera y  segunda  línea  en  la  infección  por  Helicobacter  pylori.
Métodos:  Dos  investigadores  realizaron  la  revisión  independiente  en  motores  de  búsqueda
electrónica  (PUBMED,  EMBASE,  MEDLINE)  de  ensayos  clínicos  publicados  entre  1990  y  2012,
incluyendo  adultos  e  idiomas  inglés  y  espan˜ol.
Resultados:  Se  evaluaron  43  ensayos  clínicos  (n  =  8,123),  que  incluyen  terapias  triples,  cuádru-
ples y  secuenciales,  de  primera  y  segunda  línea.  Las  tasas  de  erradicación  de  la  terapia  triple
estándar  son  inaceptables  (≤  80%)  en  países  donde  el  H.  pylori  presenta  alta  resistencia  a  clar-
itromicina  y  metronidazol.  Un  tiempo  mayor  a  7  días  no  mejora  la  eﬁcacia  de  la  triple  terapia
estándar.  No  se  observaron  diferencias  signiﬁcativas  entre  las  tasas  de  erradicación  de  la  terapia
cuádruple  con  bismuto  y  la  triple  terapia  estándar.  Aunque  las  terapias  secuencial  y  concomi-
tante son  regímenes  igualmente  exitosos,  la  terapia  triple  con  levoﬂoxacino  ofrece  los  mejores
resultados como  primera  y  segunda  línea,  pero  la  resistencia  a  quinolonas  puede  disminuir  su
eﬁcacia. La  triple  terapia  con  levoﬂoxacino,  la  secuencial  y  la  concomitante  fueron  superiores
al esquema  triple  estándar  como  régimen  de  primera  línea.
Conclusiones:  Actualmente  no  existe  un  tratamiento  óptimo  de  primera  o  segunda  línea  que
logre una  erradicación  del  100%.  El  orden  terapéutico  deberá  realizarse  acorde  al  tratamiento
inicial y  a  estudios  locales  de  resistencia  antimicrobiana.
© 2012  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Todos los  derechos  reservados.
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Infection due to Helicobacter pylori (H. pylori) affects approx-
imately 50% of the worldwide population, especially in the
developing countries. It has a great impact, reaching a prevalence
of up to 90% in the adult population.1--5 This bacterium has a
causal relation to mucosa-associated lymphoid tissue (MALT) lym-
phoma and gastroduodenal ulcer, as well as an associative relation
to pathologies such as functional dyspepsia, gastritis, and gastric
adenocarcinoma.6--8
Among the different therapies for treating H. pylori are the
standard triple therapy, which is a proton pump inhibitor (PPI) and
2 out of 3 antibiotics (amoxicillin or clarithromycin or metron-
idazole/tinidazole), bismuth-containing quadruple therapy (PPI,
bismuth, tetracycline, and metronidazole), levoﬂoxacin-containing
triple therapy (PPI, levoﬂoxacin, and amoxicillin), sequential
therapy (PPI plus amoxicillin followed by PPI, clarithromycin
and metronidazole or tinidazole), and concomitant or quadru-
ple therapy without bismuth, which is a PPI, clarithromycin,
amoxicillin, and metronidazole.7,9 The standard triple therapy cur-
rently has unacceptable H. pylori eradication levels under the 80%
intention-to-treat (ITT) rate. This is mainly due to the increased
resistance to clarithromycin and metronidazole.7,9 According to
the Maastricht IV consensus,10 the standard triple therapy, or
the bismuth-containing quadruple therapy as an alternative, have
been recommended as ﬁrst-line treatment in regions with a resis-
tance to clarithromycin under 15 to 20%, while the quadruple
therapy with bismuth or the triple therapy with levoﬂoxacin
are recommended as second-line therapies. On the other hand,
in regions in which clarithromycin resistance is greater than
15 to 20%, the indicated ﬁrst-line therapeutic regimens include
the bismuth-containing quadruple therapy, the sequential ther-
apy, and the concomitant or quadruple therapy without bismuth,
d
A
thile the triple therapy with levoﬂoxacin is used as second-line
herapy.11--16
Taking into account the prevalence and potential clinical conse-
uences of this chronic infection, it is of the utmost importance
o identify the ideal treatment regimens that achieve excellent
radication percentages.1 However, the success rates vary greatly
orldwide and there is no consensus on their effectiveness. No
deal ﬁrst-line treatment or treatment after a failed ﬁrst eradication
ttempt has been clearly determined, and there are discrepancies
n relation to optimum duration, doses, and the medication to use
n each line of therapy.9,17
The aim of the present study was to provide a systematic
eview of the international literature that includes randomized and
on-randomized clinical trials in order to evaluate the eradica-
ion effectiveness of the current ﬁrst and second-line therapeutic
egimens in the management of adults presenting with H. pylori
nfection.
ethods
earch  strategy
wo  researchers  (J.D.Forero  and  M.Rey)  independently
earched  the  electronic  databases  (PubMed,  EMBASE,  MED-
INE)  containing  studies  published  within  the  time  frame
f  1990  to  2012,  including  randomized  and  non-randomized
linical  trials  on  adults  above  the  age  of  18  years  in  both
nglish  and  Spanish.  The  electronic  bibliographic  search  was
one  using  the  following  MeSH  terms:  Helicobacter  pylori
ND  treatment  OR  therapy  AND  eradication  AND  ﬁrst-line
reatment  AND  second-line  treatment.
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(424) Studies were
identified in the
initial search
(353) Studies were excluded due to:
pediatric population inclusion,
design other than clinical trial,
incomplete study availability,
and written in a language other
than English or Spanish
(71) A complete evaluation
of the clinical trials was
carried out
(43) Clinical trials were
included in the final analysis,
(31) randomized and
(12) non-randomized
(28) Studies were eliminated:
 
They did not contribute anything
to the study aims: (10)
Third or fourth-line treatment: (4)
Evaluation of patients with more
than one previous therapeutic
failure: (4)
 
Dual therapies:  (7)
Eradication confirmation less than
four weeks: (3)
Figure  1  Flow  diagram  of  the  studies  identiﬁed  in  the  sys-
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Study  descriptions
A total of 8,123 participants were included in the 43 clinical trials0  
linical  trial  selection  criteria
1.  Randomized  and  non-randomized  clinical  trials.
2.  Eradication  rate  evaluation  in  ﬁrst-line  treatments.
3.  Eradication  rate  evaluation  in  second-line  treatments  in
the  context  of  an  initial  therapeutic  failure.
4.  Triple,  quadruple,  or  sequential  therapies  with  a  variety
of  doses,  durations,  and  medications  employed.
5.  Patients  with  H.  pylori  infection  with  no  previous  treat-
ment  or  those  with  a  prior  therapeutic  failure  with
ﬁrst-line  regimens.
6.  Patients  indicated  for  H.  pylori  infection  treatment
established  according  to  the  Maastricht  IV  Consensus.
7.  Infection  demonstrated  by  at  least  one  diagnostic  test
(urea  breath  test,  stool  antigen  test,  histologic  test,
rapid  urease  test  or  culture).
8.  Eradication  conﬁrmed  by  at  least  one  diagnostic  test
carried  out  at  a  minimum  of  4  weeks  after  having  taken
the  last  medication.
9.  An  eradication  effectiveness  report  in  an  intention-to-
treat  (ITT)  or  per-protocol  (PP)  analysis.
0.  A  report  of  the  number  of  treated  patients  and  the
number  of  cured  patients.
limination  criteria
he  clinical  trials  that  evaluated  patients  with  multiple  pre-
ious  treatment  failures  were  excluded,  along  with  trials  in
hich  the  different  medications  and  therapy  durations  were
ot  clearly  indicated  or  when  the  number  of  treated  and/or
ured  patients  could  not  be  clearly  calculated.  Resistance  to
ntibiotics,  adverse  effects,  or  adherence  to  ﬁrst  or  second-
ine  treatments  were  not  included  in  the  systematic  review.
ata  extraction  process  and  deﬁnitions
n  each  study,  the  following  variables  were  collected  on  a
tandardized  format,  summarizing  the  included  articles:
.  Author.
.  Region  of  origin.
.  Year.
.  Study  design.
.  First-line  regimens  (doses  and  days).
.  Second-line  regimens  (doses  and  days).
.  Number  of  patients  included.
.  Eradication  in  ITT  analysis,  patients  treated  and  cured.
.  Eradication  in  PP  analysis,  patients  treated  and  cured.
All  the  patients  that  had  begun  therapy  and  had  initially
een  assigned  with  or  without  randomization  were  included
n  the  ITT  analysis.  The  PP  analysis  was  carried  out  according
o  the  ﬁnal  therapeutic  regimen  adhered  to  by  the  patient,
egardless  of  the  dose.
The  methodological  quality  of  the  clinical  trials  included
n  the  study  was  evaluated  using  the  Jadad  scale.18 This
alidated  scale  includes  3  evaluation  directives:  randomiza-
ion,  blinding,  and  a  description  of  the  patients  that  were
emoved  from  or  that  abandoned  the  study.  Its  score  is  from
 to  5,  a  higher  score  representing  a  higher  study  quality.  A
andomized  clinical  trial  is  considered  to  be  of  poor  quality
f  it  has  a  score  under  2.
t
dematic  review.
tatistical  analysis
escriptive  statistics  (the  eradication  proportion  reported
n  the  intention-to-treat  [ITT]  or  per-protocol  [PP]  analy-
is)  were  used  to  summarize  and  describe  the  effectiveness
ata  of  the  clinical  trials.  A  p  <  0.05  was  used  to  determine
he  statistical  signiﬁcance  in  all  the  therapeutic  regimens
ncluded  in  the  study.
esults
ummary  of  the  included  studies
he initial search strategy identiﬁed 424 articles, 353 of which were
xcluded. Seventy-one potential clinical trials were identiﬁed, and
fter a thorough analysis, 28 were eliminated. The most common
easons for exclusion were studies that evaluated third or fourth-
ine eradication therapy regimens, the inclusion of patients with
ore than one previous failed therapy, dual therapies, eradication
onﬁrmation in a period of less than 4 weeks from the time of the
ast medication taken, or studies that did not ﬁt the aims of the
eview. Forty-three clinical trials were included in the ﬁnal analysis
ﬁgure 1).hat ﬁt the inclusion criteria of the systematic review; 31 were ran-
omized clinical trials representing a total of 6,708 patients and 12
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were non-randomized clinical trials with 1,415 patients. The clinical
trial characteristics and results are summarized in Tables 1 and 2.
Geographically, the different studies were conducted in the
United States, the United Kingdom, and Australia (4); Latin
America (11); Italy (4); Spain (4); Turkey, Tunisia, Israel, and Greece
(6); Japan, Taiwan, China, and South Korea (12). The treatments
were ﬁrst and second-line, with a duration of 1 to 14 days. All the
randomized studies were prospective and open studies.
Randomized  clinical  trials
Three clinical trials conducted in the United Kingdom, the United
States, and Greece compared the standard triple regimen using
clarithromycin with the bismuth-containing quadruple therapy as
ﬁrst-line treatments. In the United Kingdom, the eradication rates
in the ITT analysis of the standard triple regimen versus the bismuth-
containing quadruple therapy of 7-day duration were 92 and 91%,
respectively; in the United States the ITT analysis resulted in rates
of 83.2 and 87.7%, respectively, with a 10-day treatment.19,20. In
Greece, with a treatment of 10 days, the ITT eradication percent-
age for the triple therapy was 78% and it was 65% for the quadruple
therapy.21 In China, the PP analysis of one-day quadruple therapy
(PPI, bismuth, metronidazole, and amoxicillin) compared with 7-day
standard triple therapy with clarithromycin, resulted in effective-
ness rates of 39.5 and 84.6%, respectively.22 In Australia, a random
comparison of 14-day triple therapy with bismuth, 7-day quadruple
therapy with bismuth, and 7-day standard triple therapy with clar-
ithromycin in 405 patients produced ITT eradication rates for each
therapy of 69, 82, and 78%, respectively. The bismuth-containing
quadruple therapy and the standard triple therapy had similar erad-
ication rates; however, the bismuth-containing quadruple therapy
was superior to the triple therapy with bismuth.23
Three clinical trials conducted in the United States, Japan, and
Tunisia compared the eradication rates of different regimens of the
standard triple therapy as ﬁrst-line treatment. In the United States,
the effectiveness of the standard triple therapy with rabeprazole
for 3, 7, and 10 days and omeprazole for 10 days had eradica-
tion percentages in the ITT analysis as follows: 3 days 27%, 7 days
77%, and 10 days with rabeprazole 78% and 10 days with omepra-
zole 73%. There was no statistically signiﬁcant difference between
the 7-day regimen with rabeprazole and the 10-day regimens with
rabeprazole and omeprazole.24 In Tunisia, the ITT eradication rates
of the classic triple regimen with clarithromycin versus metronida-
zole of 7-day duration were 48.7 and 69.6%, respectively.25 In Japan,
the ITT success rates of the standard triple therapy (omeprazole,
amoxicillin, and clarithromycin) compared with the dual therapy
(omeprazole and clarithromycin) of 14-day duration were 73.6 and
55%, respectively.26
Five randomized clinical trials from Mexico, Italy, and Turkey
were reviewed, comparing the eradication rates of therapies based
on quinolones. In the Mexican population the triple therapy with
oﬂoxacin as ﬁrst-line therapy at a dose of 800 mg per day for 14
days, compared with a duration of 7 days, produced eradication
rates in the ITT analysis of 92.3 and 62.2%, respectively, with a sta-
tistically signiﬁcant difference.27 In Italy, as a ﬁrst-line regimen, the
standard triple therapy with moxiﬂoxacin at a dose of 800 mg per
day and durations of 5, 7, and 10 days, and 400 mg of moxiﬂoxacin
for 10 days, had eradication rates in the ITT analysis as follows:
5 days 71.4%, 7 days 80.3%, 10 days with 800 mg of moxiﬂoxacin
per day 90.4%; and 10 days, 80% with 400 mg of moxiﬂoxacin per
day. There was a statistically signiﬁcant difference between the
triple therapy with moxiﬂoxacin at a 10-day dose of 800 mg per
day and the other therapeutic regimens.28 Additionally, in Italy the
eradication rates of the triple therapies (PPI, clarithromycin, and
metronidazole) versus (PPI, amoxicillin, and clarithromycin) versus
(PPI, levoﬂoxacin, and amoxicillin) for 7 days reached the respec-
tive ITT eradication rates of 75, 72, and 87%, whereas the triple
c
d
B
f31
herapy with levoﬂoxacin showed a statistically signiﬁcant differ-
nce in relation to the other therapeutic regimens.29 In Turkey, the
ffectiveness as ﬁrst-line treatments of the 2 triple therapies with
evoﬂoxacin at different doses (500 g/day versus 1 g/day) had ITT
uccess rates of 60 and 72.7%, respectively, even though the differ-
nce between the 2 groups was not statistically signiﬁcant.30 Also
n Turkey, the standard triple therapy with clarithromycin versus
he sequential therapy with levoﬂoxacin for 14 days reached an ITT
uccess rate of 50.7 and 90.2%, respectively.31
Nine randomized clinical trials conducted internationally, with
 total of 1,322 patients, compared the effectiveness of differ-
nt second-line regimens after a ﬁrst failed eradication attempt
ith the standard triple therapy using clarithromycin, obtaining
he following results: In Japan, the eradication rates in the ITT
nalysis of the standard triple therapy with metronidazole for
 and 7 days were 95.1 and 95.2%, respectively; with doses of
etronidazole of 500 mg/day versus 750 mg/day, the success rates
or each regimen in the ITT analysis were 87.3 and 86.9%.32,33
ther Japanese studies compared the eradication rates of the
tandard triple therapy with metronidazole and the triple ther-
py with famotidine, and the concomitant or quadruple therapy
ithout bismuth for 7 days; the eradication rate in the ITT anal-
sis for the standard triple therapy with metronidazole was 97%
ersus 94% for the triple therapy with famotidine; in the ITT/PP
nalyses for the standard triple therapy with metronidazole the
radication rate was 88.5%-93.9% versus 82.7%-84.3% for the conco-
itant or quadruple therapy without bismuth.34,35 In Spain, the
ismuth-based quadruple therapy versus the rifabutin-based triple
herapy, both of 7-day duration, achieved eradication percent-
ges in the ITT analysis of 70.4 and 44.4%, respectively.36 In South
orea, the 7-day bismuth-containing quadruple therapy versus the
ame 14-day therapy showed effectiveness in the ITT analysis
f 64.3 and 82.6% respectively.37 In Turkey, the 14-day quadru-
le therapy with a PPI and bismuth plus 2 different antibiotics
amoxicillin-metronidazole versus amoxicillin-tetracycline versus
etronidazole-tetracycline) produced eradication rates in the PP
nalysis of 74.1, 81.5, and 82.1%, respectively, with no statistically
igniﬁcant differences between the therapeutic regimens.38 In Tai-
an, the standard bismuth-based quadruple therapy (PPI, bismuth,
etracycline, and metronidazole) versus the quadruple therapy (PPI,
ismuth, tetracycline, amoxicillin), both of 7-day duration, had the
espective eradication rates in the ITT analysis of 81 and 62%.39
nd ﬁnally, in the Spanish population, the triple therapy with raniti-
ine bismuth citrate (RBC), tetracycline, and metronidazole versus
he triple therapy with levoﬂoxacin were effective in 69 and 71%,
espectively, with no statistically signiﬁcant differences.40
Of the Latin American randomized clinical experiments included
n the study, the following eradication rates for the clarithromycin-
ased standard triple therapy as ﬁrst-line treatment were obtained:
n Colombia, the effectiveness of 7-day versus 14-day treatment
eached ITT eradication rates of 67.8 and 74.3%, respectively;41 in
hile, 7-day versus 14-day treatment had rates of 78.3 and 85.5%;42
n Ecuador, 7-day versus 10-day treatment, 68.3 and 83.8%;43 and in
razil, the standard triple therapy with clarithromycin versus a con-
rol group (PPI plus placebo), both of 10-day duration, had rates of
8.6 and 7.4%, respectively.44 As second-line therapy, in Colombia,
he 14-day clarithromycin-based triple therapy with lansoprazole
ersus omeprazole reached eradication rates of 69 and 70% in each
espective regimen, with no statistically signiﬁcant difference.45
he standard triple therapy, compared with the 7-day concomitant
herapy versus 14 days as ﬁrst-line therapies, had the respective
radication rates of 86.3 versus 96.7% in the PP analysis.46 Addi-
ionally, in a study conducted in different Latin American countries,
he eradication rates of the standard triple therapy for 14 days, the
oncomitant therapy for 5 days, and the sequential therapy for 10
ays were 82.2, 73.6, and 76.5% in the ITT analysis.47 Finally, in
razil, the triple therapy with furazolidone (PPI plus clarithromycin)
or 7 days had signiﬁcantly higher ITT eradication rates with 400 mg
32
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Table  1  Randomized  clinical  experiments  that  evaluate  ﬁrst-line  or  second-line  regimens  for  the  treatment  of  Helicobacter  pylori  infection.
Author  Region  Year  Study
design
Type  of
disease
First-line  regimens
(doses  and  days)
Second-
line
rescue
regimens
(doses
and
days)
Patients
included
(n)
Eradication
(%)  (ITT)
95%CI
Eradication
(%)  (PP)
95%CI
Jadad
score
(0-5)
Ching
et  al.19
The
United
Kingdom
2008  RCT  PUD,
NUD,
gastritis
1)  La  30  mg/q12h
+ A  1  g/q12h  +  C
500  mg/q12  h  x  7
2)  La  30  mg/q12h
+ B  240mg/q12h  +
M 400  mg/q8h  +  T
500  mg/q6  h  x  7
--  94
1)  50
2)  44
1)  46/50
(92)
2)  40/44
(91)
p >  0.05
1)  46/50
(92)
2)  37/38
(97
3
Laine
et al.20
The
United
States
2003  RCT  PUD  1)  O  20  mg/q12h  +
B 140mg/q6  h  +
M125mg/q6h  +  T
125  mg/q6h  x10
2) O  20  mg/12h  +
A  1  g/q12h  +  C  500
mg/q12  h  x  10
--  275
1)  138
2)  137
1)
121/138
(87.7)
82.2--93.2
114/137
(83.2)
77.0--89.5
p  =  0.29
1)
111/120
(92.5)
(87.8--97.2)
2)
108/124
(87.1)
(81.2--93.0)
p  =  0.16
3
Mantzaris
et al.21
Greece  2002  RCT  Duodenal
ulcer
1)  O  20  mg/q12h  +
A 1g/q12h  +  C  500
mg/q12h  x  10
2)  O  20  mg/q12h  +
B 120  mg/q6h  +  M
500  mg/q8  h  +  T
500/q6h  x  10
--  149
1)  78
2)  71
1)  61/78
(78)
68--88
2)  46/71
(65)
47--83;  p
0.1
1)  61/69
(88)
(80--96)
2)  46/59
(78)
77--79;  p
0.2
4
Zheng
et al.22
China  2005  RCT  NUD  1)  E  40  mg/q12h  +
B 440  mg/q6h  +  A
2  g/q6h  +  M  400
mg/q6h  x  1
2)  E  20  mg/q12h  +
A 1  g/q12  h  +  C
500  mg/q12  h  x  7
--  80
1)  39
2)  41
1)15/39
(38.5)
25--54
2)  33/41
(80.5)
66--90
p =  0.0002
1)  15/38
(39.5)
26--55
2)  33/39
(84.6)
66--90
p <  0.0001
3
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Table  1  (Continued)
Author  Region Year Study
design
Type  of
disease
First-line  regimens
(doses  and  days)
Second-
line
rescue
regimens
(doses
and
days)
Patients
included
(n)
Eradication
(%)  (ITT)
95%CI
Eradication
(%)  (PP)
95%CI
Jadad
score
(0-5)
Katelaris
et  al.23
Australia  2002  RCT  NUD  1)  P  40  mg/q12h  +  A  1
g/q12h  +  C  500
mg/q12  h  x  7
2)  P  40  mg/q6h  +  B
108  mg/q6  h  +
M1g/q24h  +  T  500
mg/q6  h  x7
3)  B  108  mg/q6  h  +
M1g/24h  +  T  500
mg/q6  h  x  14
-- 405
1)  134
2)  134
3)137
1)
104/134
(78)
2)
110/134
(82)
3)
95/137
(69)
82%
versus
69%
p  <  0.01
82%
versus
78%
p  >  0.05
1)
94/114
(82)
2)
92/105
(88)
3)
75/101
(74)
4
Vakil et  al.24 The
United
States
2004  RCT  NUD,
PUD
1)  Ra  20  mg/q12h+  A
1 g/q12h+  C  500
mg/q12h  x3
2)  Ra  20  mg/q12h+  A
1 g/12h+  C  500  mg
/q12h  x  7
3) Ra  20  mg/q12h+  A
1 g/q12h+  C  500  mg
/q12h  x  10
4) O  20  mg/q12h+  A  1
g/q12h+  C  500  mg
/q12h  x  10
-- 803
1)194
2)  200
3)  202
4)  207
1)51/187
(27)
(21-34)
2)150/194
(77)
(71-83)
3)153/196
(78)
(72-84)
4)151/206
(73)
(67-79)
1)
50/167(23)
(23-37)
2)
140/166(84)
(79-90)
3)147
/171(86)
(81-91)
4)
146/179
(82)
(76-87)
5
Loghmari
et al.25
Tunisia  2012  RCT  PUD,
NUD
1)  O  20  mg/q12h+  A  1
g/q12h+  C  500  mg
/q12h  x  7
2) O  20  mg/q12h  +  A
1 g/12h  +  M  500  mg/
q12h  x  7
--  120
1)  60
2)  60
NR  1)  32/46
(69.6)
2)  19/39
(48.7)
p <  0.05
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Table  1  (Continued)
Author  Region  Year  Study
design
Type  of
disease
First-line
regimens
(doses  and
days)
Second-line
rescue
regimens
(doses  and
days)
Patients
included
(n)
Eradication
(%)  (ITT)
95%CI
Eradication
(%)  (PP)
95%CI
Jadad
score
(0-5)
Habu
et  al.26
Japan  1998  RCT  PUD  1)  O  20
mg/q12h  +  A
500  mg/q6h  +  C
400  mg/q12h  x
14
2)  O  20  mg/q12
h +  C  400
mg/q12h  x  14
--  234
1)  125
2)  109
1)  92/125
(73.6)
66--81
2)  60/109
(55.0)
46--64;
p <  0.001
1)  60/97  (87.6)
81--94
2)  60/109
(61.9)
52--72;
p <  0.001
3
Bosques --
Padilla
et  al.27
Mexico  2004  RCT  NUD,
PUD
1)  Ra  20
mg/q12h  +  A  1
g/q12  h  +  Of
400  mg/q12  h  x
7
2)  Ra  20
mg/q12h  +  A  1
g/q12  h  +  Of
400  mg/q12  h  x
14
--  76
1)  37
2)  39
1)  23/37  (62.2)
46.1--76
2)  36/39  (92.3)
79--98.1
p  =  0.04
1)  23/36  (63.9)
47.5--77.6
2)  36/37  (97.3)
85--100
p  =  0.01
Sacco
et al.28
Italy  2009  RCT  1)  E  20
mg/q12h  +  A  1
g/12h  +  Mo  400
mg/q12  h  x  10.
2) E  20  mg/q12
h +  A  1  g/12h  +
Mo  400  mg/q12
h x  7.
3) E  20  mg/q12
h +  A  1  g/q12h
+ Mo  400
mg/q12h  x  5.
4)  E  20
mg/q12h  +  A  1
g/q12h  +  Mo
400  mg/q  24h  x
10.
5)  E  20
mg/q12  h  +
A  1  g/q12h
+ Mo  400
mg/q12h  x
10.
6)  E  20
mg/q12  h  +
A  1  g/q12h
+ Ri  150
mg/q12h  x
10.
393
1)  94
2)  102
3)  92
4)  105
5)  30
6)19
1)  85/94  (90.4)
84.4--96.4
2)  82/102
(80.3)
71.5--86.3
3)  70/98  (71.4)
62.3--80.5
4)  84/105  (80)
72.3--87.7
p <  0.05
90.4  vs.  80.3
p  <  0.01
90.4  vs.  71.4
p  <  0.05
90.4  vs.  80
5)  26/30  (86.7)
69.7--95.3
6)  16/19  (84.2)
61.6--95.3
1)  85/90  (94.4)
89.6--99.2
2)  82/96  (85.5)
77.5--91.4
3)  70/93  (75.2)
66.4--84.0
4)  84/99  (84.8)
77.7--91.9
p  <  0.05  1  vs.  2
p  <  0.01  1  vs.  3
p  <  0.04  1  vs.  4
5)  26/28  (92.2)
76.2--99.1
6)  (16/19)
(84.2)
61.6--95.3
3
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Table  1  (Continued)
Author  Region Year Study
design
Type  of
disease
First-line  regimens
(doses  and  days)
Second-line
rescue
regimens
(doses  and
days)
Patients
included
(n)
Eradication
(%)  (ITT)
95%CI
Eradication
(%)  (PP)
95%CI
Jadad
score
(0-5)
Nista
et  al.29
Italy  2006  RCT  NUD,
PUD
1)  E  20  mg/q12h  +  A
1g/q12h  +  C  500
mg/q12h  x  7
2)  E  20  mg/q12h  +  C
500 mg/q12h  +  M  500
mg/q12h  x  7
3)  E  20  mg/q12h  +  C
500 mg/q12  h  +  L  500
mg/q24h  x  7
-- 300
1)  100
2)  100
3)  100
1)
75/100
(75)
69-81
2)
72/100
(72)
67-78
3)
87/100
(87)
81-93
87%  vs.
75%;
p  <  0.05;
87%  vs.
72%;
p  <  0.01
75%  vs.
72%
p  >  0.05
1)  75/95
(79)
73-85
2)  72/93
(77.4)
71.4-
84.4
3)  87/96
(90.6)
84.6-
96.6
90.6%  vs.
79%,
p <  0.05;
90.6  vs.
77.4;
p  <  0.05
79%  vs.
77.4%
p  >  0.05
3
Seven
et al.30
Turkey  2011  RCT  PUD,
gastric
cancer,
MALT,
others
1)  L  500  mg/q24h  +  A
1 g/q12h  +  PPI/q12h
x  10
2)  L  500  mg/q12h  +  A
1 g/q12h  +  PPI/q12h
x  10
--  110
1)  60
2)  50
1)  36/60
(60)
54-64
2) 36/50
(72)
66-78
p =  0.427
1)  36/60
(60)
54-64
2)  36/50
(72)
66-78
p =  0.427
3
Polat
et al.31
Turkey  2011  RCT  NUD  1)  (E  40  mg/q12h  +  A
1 g/q12h  x  7)  +  (E  40
mg/q12h  +  L
500/q6h+  M  500
mg/q8h  x  7)
2)  E  40  mg/q12  h  +  A
1 g/q12h  +  C  500
mg/q12  h  x  14
--  139
1)  72
2)  67
1)  65/72
(90.2)
83--96
2) 34/67
(50.7)
44--57;
p =  0.000
1)  65/72
(90.2)
83--96
2)  34/67
(50.7)
44--57;
p =  0.000
3
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Table  1  (Continued)
Author  Region  Year  Study
design
Type  of
disease
First-line
regimens
(doses  and
days)
Second-line
rescue
regimens
(doses  and
days)
Patients
included
(n)
Eradication
(%)  (ITT)
95%CI
Eradication
(%)  (PP)
95%CI
Jadad
score
(0-5)
Fukuda
et  al.32
Japan  2006  RCT  PUD  PPI+A+C  1)  La
30mg/q12h  +  A
750  mg/q12h  +
M  250  mg/q12h
x 5
2)  La
30mg/q12h  +  A
750  mg/q12h  +
M  250  mg/q12h
x 7
83
1)  41
2) 42
1)  39/41
(95.1)
61.6--95.3
2) 40/42
(95.2)
61.6--95.3;
p >  0.05
1)  39/41
(95.1)
61.6--95.3
2)  40/42
(95.2)
61.6--95.3;
p >  0.05
3
Matsuhisa
et al.33
Tokyo  2006  RCT  NUD,
PUD,
gastric
cancer,
others
PPI+A+C  1)  PPI  (O  20
mg/q12h  or  La
30mg/q24h  or
R 10  mg/q12h)
+  A  750
mg/q12h  +  M
250  mg/q12h  x
7
2)  PPI  (O  20
mg/q12h  or  La
30mg/q24h  or
R 10  mg/q12h)
+  A  750
mg/q12h  +  M
750  mg/q24h  x
7
228
1)  121
2) 107
1)
106/121
(87.6)
81.7--93.5
2)
93/107
(86.9)
80.5--93.3
p  =  0.876
1)
106/117
(90.6)
85.3--95.9
2)
93/105
(88.6)
82.5--94.7
p  =  0.621
3
Murakami
et al.34
Japan  2006  RCT  NUD,
PUD
PPI+A+C  1)  La
30mg/q12h  +  A
750  mg/q12h  +
M  250  mg/q12h
x 7
2)  Fa
40mg/q12h  +  A
750  mg/q12h  +
M  250  mg/q12h
x 7
61
1)  30
2) 31
1)  29/30
(97)
83--99
2) 29/31
(94)
80--99;
p >  0.05
1)  29/30
(97)
83--99
2)  29/31
(94)
80--99;
p >  0.05
3
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Table  1  (Continued)
Author  Region Year Study
design
Type  of
disease
First-line
regimens
(doses  and
days)
Second-line  rescue
regimens
(doses  and  days)
Patients
included
(n)
Eradication
(%)  (ITT)
95%CI
Eradication
(%)  (PP)
95%CI
Jadad
score
(0-5)
Ueki  et  al.35 Tokyo 2009  RCT  PUD,
NUD,
others
PPI+A+C  1)  R  10  mg/q12h  +
A 750  mg/q12h  +
M  250  mg/q12h  +
C  200  mg/q12h  x  7
2) R  10  mg/q12  h  +
A 750  mg/q12h  +  M
250  mg/q12  h  x  7
104
1)  52
2)  52
1)  45/52
(88.5)
79.7--97.3
2) 43/52
(82.7)
72.7--92.7
p =  0.407
1)  46/49
(93.9)
87.1--100
2) 43/51
(84.3)
74.3--94.3
p =  0.129
4
Navarro-
Jarabo
et al.36
Spain  2007  RCT  PUD,
NUD
PPI+A+C  1)  O  20  mg/q12h  +
B 120/q6h  +  T  500
mg/q6h  +  M  500
mg/q8h  x  7
2)  O  20  mg/q12h  +
A 1  g/q12h  +  Ri
150  mg/q12h  x  7
99
1)  54
2)  45
1)
38/54(70.4)
2)
20/45(44.4)
p  =  0.009
1)
37/48(77.1)
2)
20/43(46.5)
p  =  0.002.
3
Lee et  al.37 South
Korea
2010  RCT  PUD,NUD,
gastric
cancer,
others
PPI+A+C  1)  E  20mg/q12h  +
B 300/q6h  +  T  500
mg/q6h  +  M  500
mg/q8h  x  7
2)  E  20mg/q12h  +
B 300/q6h  +  T  500
mg/q6h  +  M  500
mg/q8h  x  14
227
1)  112
2)  115
1)72  /
112
(64.3)
0,504  a
0,830
2)  95  /
115
(82.6)
1.165--2.499
p  =  0.001
1)  71  /
92  (77.2)
44--74.9
2) 88  /
94  (93.6)
1.213--5.113
p =  0.01
3
Uygun
et al.38
Turkey  2008  RCT  NUD  PPI+A+C  1)  La  30mg/q12h  +
B 300/q6h  +  A  1
g/q12h  +  M  500
mg/q12  h  x  14
2)  La  30mg/q12h  +
B 300/q6h  +  A  1
g/q12h  +  T  500
mg/q6  h  x  14
3)  La  30mg/q12h  +
B 300/q6h+  M  500
mg/q12  h  +  T  500
mg/q6  h  x  14
300
1)  100
2)  100
3)  100
NR  1)  68/91
(74.7)
2) 75/92
(81.5)
3) 78/95
(82.1)
p >  0.05
3
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Table  1  (Continued)
Author  Region  Year  Study
design
Type  of
disease
First-line  regimens
(doses  and  days)
Second-line
rescue
regimens
(doses  and
days)
Patients
included
(n)
Eradication
(%)  (ITT)
95%CI
Eradication
(%)  (PP)
95%CI
Jadad
score
(0-5)
Wu  et  al.39 Taiwan  2011  RCT  PUD,
NUD
PPI+A+C  1)  E  40
mg/q12h  +  B
120/6qh  +  T
500  mg/q6h  +  A
500  mg/q6h  x  7
2)  E  40mg/q12h
+  B  120/q6h  +  T
500  mg/q6h  +
M 250  mg/q6  h
x  7
120
1)  62
2)  58
1)  38/62
(62)
50-75
2)  47/58
(81)
71-91
p =  0.02
1)  49/  59
(83)
74-92
2)  35/55
(64)
52-76
p  =  0.01
4
Gisbert
et al.40
Spain  2007  RCT  PUD,
NUD
PPI+A+C  1)  RBC  400
mg/q12h  +  T
500  mg/q6h  +
M 250  mg/q6h
x  5
2)  L  500
mg/q12h  +  A  1
g/q12h  +  O  20
mg/q12h  x  7
100
1)  50
2)  50
1)
34/50(68)
59--79
2)
34/50(68)
59--79
p  >  0.05
1)
31/45(69)
54--80
2)
32/45(71)
57--82
p  >  0.05
3
Castan˜o
et al.41
Colombia  2012  RCT  PUD,
NUD
1)  O  20  mg/q12h  +
A 1  g/q12h  +  C  500
mg/q12  h  x  7
2)  O  20  mg/q12h  +
A 1  g/12h  +  C  500
mg/q12  h  x  14
--  293
1)  149
2)  144
1)
101/149
(67.8)
68--88
2)
107/144
(74.3)
47--83;
p  =  0.247
1)
98/136
(72.05)
80--96
2)
99/122
(81.14)
77--79;  p
0.2
p  =  0.086
3
Riquelme
et al.42
Chile  2007  RCT  PUD,
NUD
1)  O  20  mg/q12h  +
A 1  g/12  h  +  C  500
mg/q12  h  x  7
2)  O  20  mg/q12h  +
A 1  g/12  h  +  C  500
mg/q12  h  x  14
--  131
1)  69
2)  62
1)  54/69
(78.3)
2)  53/62
(85.5)
9%-23%
p =  0.37
1)  54/63
(87.5)
2)  53/60
(88.3)
p  =  0.37
3
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Table  1  (Continued)
Author  Region Year Study
design
Type  of
disease
First-line  regimens
(doses  and  days)
Second-line
rescue
regimens
(doses  and
days)
Patients
included
(n)
Eradication
(%)  (ITT)
95%CI
Eradication
(%)  (PP)
95%CI
Jadad
score
(0-5)
Robles-Jara
et  al.43
Ecuador  2008  RCT  NUD,
PUD,
others
1)  O  20  mg/q12h  +
A 1  g/12  h  +  C  500
mg/q12  h  x  7
2)  O  20  mg/q12h  +
A 1  g/12h  +  C  500
mg/q12  h  x  10
-- 1)  65
2)  62
1)  44/65  (68)
66.9-73.8
2)  52/62  (83.8)
82.7-89.6
p  =  0.03
1)  44/65
(68)
66.6-78
2)  46/52
(88)
86.4-98
p =  0.008
3
Mazzoleni
et al.44
Brazil  2011  RCT  Functional
dyspep-
sia
1)  O  20  mg/q12h  +
A 1  g/12h  +  C  500
mg/q12  h  x  10
2)  O  20  mg/q12h  +
placebo  x  10
-- 404
1)  201
2)  203
1)  164/201
(88.6)
2) 14/203  (7.4)
p  <  0.01
-- 5
Mera et  al.45 Colombia  1999  RCT  Atrophic
gastritis
B  262mg/q6h  +  A
500mg/q8h  +  M
400  mg/q8h  x  14
1)  La  30
mg/q12h  +  A  1
g/q12h  +  C  500
mg/q12h  x  14
2)  O  30
mg/q12h  +  A  1
g/q12h  +  C  500
mg/q12h  x  14
143
1)  81
2)  62
1)  (69)
2) (70)
114/143  (79.7)
72-85
p  >  0.05
-- 3
Fischbach
et al.46
Colombia  2009  RCT  Atrophic
and  non-
atrophic
gastritis
1)  O  20  mg/q12h  +
A 500  mg/q8h  +  C
500  mg/q12h  +  M
500  mg/q8h  x  14
2) O  20  mg/q12h  +
A 1  g/q12h  +  C  500
mg/12  h  x  7
--  151
1)  75
2)  76
1)  65/75  (86.8)
2)  65/76  (85.3)
-9.7-12.7
p  =  0.79
1)  (96.7)
2)  (86.3)
p =  0.04
4
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Table  1  (Continued)
Author  Region  Year  Study
design
Type  of
disease
First-line  regimens
(doses  and  days)
Second-line
rescue
regimens
(doses  and
days)
Patients
included
(n)
Eradication
(%)  (ITT)
95%CI
Eradication
(%)  (PP)
95%CI
Jadad
score
(0-5)
Greenberg
et  al.47
Latin
America
2011  RCT  PUD,
NUD
1)  La  30  mg/q12h
+ A  1  g/q12h  +  C
500 mg/q12h  x  14
2)  La  230  mg/q12h
+  A  1g/q12h  +  M
500  mg/q12h  +  C
500  mg/q12h  x  5
3)  (La  230
mg/q12h  +  A
1g/q12h  x  5)  +  (La
230  mg/q12h  +  M
500  mg/q12h  +  C
500  mg/q12h  x  5)
--  1463
1)  488
2)  489
3)  486
1)  401/488
(82.2)
78.5-85.5
2) 360/489
(73.6)
69.5-77.5
3) 372/486
(76.5)
72.5-80.2
82.2%  vs.
76.5%,  p  =  0.037
82.2%  vs.
73.6%,  p  >  0.05
--  3
Coelho
et al.48
Brazil  2003  RCT  Relatives
of
patients
with
gastric
cancer
1)  L  30  mg/q24h  +
C 500  mg/q24h  +  F
400  mg/q24h  x  7
2)  L  30  mg/q24h  +
C 500  mg/q24h  +  F
200  mg/q24  h  x  7
--  79
1)  40
2)  39
1)  35/40  (87.5)
(73--96%)
2)  24/39  (61.5)
(45--77)
p  =  0.006
--  3
Sanches
et al.49
Brazil  2008  RCT  NUD,
Duodenal
ulcer
PPI+C+A/F  1)  R  20
mg/q24h  +  L
500  mg/q24h  +
F  400  mg/q24h
x  10
2)  R  20
mg/q12h  +  B
240  mg/q12h  +
D  100  mg/q12h
+  F  200  mg/12h
x 10
60
1)  31
2)  29
1)  24/31  (77)
62--93
2)  24/29  (83)
68--97
p  =  0.750
1)  24/30
(80)
65--95
2)  23/28
(82)
67--96
p =  1.0
3
A: amoxicillin; Az: azithromycin; B: bismuth; C: clarithromycin; q12 h: twice a day; q6 h: four times a day; q8 h: three times a day; q24 h: once a day; NUD: non-ulcer dyspepsia; PUD: peptic
ulcer disease; RCT: randomized clinical trial; NRCT: non-randomized clinical trial; E: esomeprazole; Fa: famotidine; F: furazolidone; PPI: proton pump inhibitor; ITT: intention-to-treat;
La: lansoprazole; L: levoﬂoxacin; Me: metronidazole; Mo: moxiﬂoxacin; NR: not reported; O: omeprazole; Of: oﬂoxacin; P: pantoprazole; PP: per-protocol; R: rabeprazole; Ri: rifabutin;
T: tetracycline; Ti: tinidazole.
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Table  2  Non-randomized  clinical  experiments  that  evaluate  ﬁrst-line  or  second-line  regimens  for  treating  Helicobacter  pylori  infection.
Author  Region Year Study
design
Type  of
disease
First-line
regimens
(doses  and
days)
Second-line
rescue
regimens
(doses  and
days)
Patients
included
(n)
Eradication
(%)  (ITT)
95%CI
Eradication
(%)  (PP)
95%CI
Jadad
score
(0-5)
Sivri
et  al.50
Turkey 2004  NRCT  Duodenal
ulcer
P  40
mg/q12h  +
A  1  g/q12h
+  C  500
mg/q12h  x  7
-- 77  49/77
(63.6)
55.6-
69.7
49/72
(68)
57--79.1
1
Felga
et al.51
Brazil  2010  NRCT  PUD  O  20
mg/q12h  +
A  1  g/q12h
+  C  500
mg/q12  h  x
7
-- 493  408/493
(82.7)
79-86
(88.8)
(86-92)
1
Luna
et al.52
Argentina  1999  NRCT  DNE,
PUD,GERD
P  40
mg/q12h  +
B  120
mg/q6h  +  M
500  mg/8h  +
T 500
mg/q6h  x  7
--  40  35/40
(87.5)
77.5-
97.5
1
Schmilovitz-
Weiss
et al.53
Israel  2011  NRCT  PUD,
NUD,
others
(O  20
mg/q12h  +
A  1  g/q12h  x
5)  +  (E  20
mg/q12h  +
C  500
mg/q12  h+
Ti  500
mg/q12  h  x
5)
-- 124  115/124
(96.8)
115/120
(95.8)
1
Ermis
et al.54
Turkey  2011  NRCT  PUD  1)  La  30
mg/q12h  +
A  1  g/q12h
+  C  500
mg/q12h  x
14
2)  O  20
mg/q12h  +  L
500
mg/q12h  +  A
1  g/q12h  x  7
1)  91
2)  37
1)  52/91
(57.14)
2) 4/37
(37.83)
1)  52/89
(58.42)
2)  14/34
(41.17)
1
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Table  2  (Continued)
Author  Region  Year  Study
design
Type  of
disease
First-line
regimens
(doses  and
days)
Second-line
rescue
regimens
(doses  and
days)
Patients
included
(n)
Eradication
(%)  (ITT)
95%CI
Eradication
(%)  (PP)
95%CI
Jadad
score
(0-5)
Gisbert
et  al.55
Spain  2010  NRCT  NUD,
allergy
to
penicillin
1)  O  20
mg/q12h  +
C  500
mg/q12h  +
M  500  mg
/q12h  x  7
2)  O  20
mg/q12h  +
C  500
mg/q12h  +  L
500  mg
/q12h  x  10
50
1)  50
2)  15
1)  27/50
(54)
39--69
2) 11/15
(73)
45--92
1)  27/49
(55)
40--70
2)  11/15
(73)
45--92
1
Pontone
et al.56
Italy  2010  NRCT  NUD  1)  (La  30
mg/q12h  +
A  1  g/q12h  x
5)  +  (C  500
mg/q12h  +
La  30
mg/q12h+  M
500
mg/q12h  x
5)
2)  La  30
mg/q12h+  L
250
mg/q12h+  A
1 g/q12h  x
10
84
1)  84
2)  7
1)  70/84
(83.3)
75.4--91.3
2) 7/7
(100)
1)  70/77
(90.9)
84.5--97.3
2)  7/7
(100)
1
Murakami
et al.57
Japan  2003  NRCT  PUD,
NUD
PPI+A+C  1)  R  20
mg/q12h  +
A  750  mg/
q12h  +  M
250
mg/q12h  x  7
1)  92  81/92
(88)
80--95
81/89
(91)
83--98
1
Hori
et al.58
Japan  2011  NRCT  PUD,
NUD,
others
PPI+A+C  1)  R  10
mg/q12h  +
A  750
mg/q12h  +
M  250
mg/q12h  x
14
1)  82  1)  65  /82
(79)
71-81
1)  65/65
(100)
94--100
1
Perna
et al.59
Italy  2007  NR  NR  PPI+A+C  1)  R  20
mg/q12h  +
A  1  g/q12h
+  L  250
mg/q12h  x
10
1)  24  1)  24  /33
(72.7)
57--88
1)  24/33
(72.7)
57--88
1
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Table  2  (Continued)
Author  Region Year Study
design
Type  of
disease
First-line
regimens
(doses  and
days)
Second-line
rescue
regimens
(doses  and
days)
Patients
included
(n)
Eradication
(%)  (ITT)
95%CI
Eradication
(%)  (PP)
95%CI
Jadad
score
(0-5)
Gisbert
et  al.60
Spain  2008  NRCT  PUD,NUD  PPI+A+C  1)  O  20
mg/q12h  +
A  1  g/q12h
+  L  500
mg/q12h  x
10
1)  300 1)
232/300
(77)
73--82
1)
232/285
(81)
77--86
1
Liou
et al.61
Taiwan  2011  NRCT  NR  PPI+A+C  1)  (E  40
mg/q12h  +
A  1  g/q12h  x
5)  +  (E  40
mg/q12h  +  L
250
mg/1q2h+  M
500
mg/q12h  x
5)
1)  142  1)
135/142(95.1)
91.5--98.6
1)
133/138
(96.4)
93.3--99.5
1
A: amoxicillin; Az: azithromycin; B: bismuth; C: clarithromycin; q12 h: twice a day; q6 h: four times a day; q8 h: three times a day; q24 h: once a day; NUD: non-ulcer dyspepsia; PUD: peptic
ulcer disease; RCT: randomized clinical trial; NRCT: non-randomized clinical trial; E: esomeprazole; Fa: famotidine; F: furazolidone; PPI: proton pump inhibitor; ITT: intention-to-treat;
La: lansoprazole; L: levoﬂoxacin; Me: metronidazole; Mo: moxiﬂoxacin; NR: not reported; O: omeprazole; Of: oﬂoxacin; P: pantoprazole; PP: per-protocol; R: rabeprazole; Ri: rifabutin;
T: tetracycline; Ti: tinidazole.
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er day of furazolidone compared with 200 mg per day of fura-
olidone (87.5% versus 61.5%); and as a second-line regimen, the
riple therapy with furazolidone (PPI, levoﬂoxacin, and furazoli-
one), administered once a day for 10 days, compared with the
uadruple therapy with furazolidone (PPI, bismuth, doxycycline,
nd furazolidone), administered twice a day, had eradication rates
n the ITT analysis of 77 and 83%, respectively.48,49
on-randomized  clinical  trials
s ﬁrst-line treatments, the eradication rates of the clarithromycin-
ased triple therapy of 7-day duration was evaluated in 2 clinical
rials: In the ﬁrst one, the cure percentage was 68% in the PP analysis
nd 63.6% in the ITT analysis;50 in the second one, the eradication
ate in the ITT analysis was 82.7% and 88.8% in the PP analysis.51
he 7-day bismuth-containing quadruple therapy had 87.5% effec-
iveness in the ITT analysis52 and the 10-day sequential therapy
ad 95.8% effectiveness in the PP analysis (115/124) and 92.7%
ffectiveness in the ITT analysis (115/120).53
Three non-randomized clinical trials also evaluated ﬁrst-line
reatment eradication rates (triple therapies with clarithromycin,
etronidazole, and sequential therapies), followed by the
evoﬂoxacin-based triple therapy as second-line treatment, obtain-
ng the following results: the standard clarithromycin-based triple
herapy for 14 days reached an efﬁciency rate of 57.14% in the ITT
nalysis and one of 37.83% in the second-line levoﬂoxacin-based
riple therapy for 7 days.54 The triple therapy with clarithromycin
nd metronidazole attained eradication in 27 out of 50 cases, with
n effectiveness of 54% in the ITT analysis, and as rescue treatment,
he levoﬂoxacin-based triple therapy achieved eradication in 11 of
he 15 cases (73%).55 The effectiveness of the sequential therapy
s ﬁrst-line therapy reached 83.3% eradication in the ITT analysis
nd 90.9% eradication in the PP analysis; as second-line therapy,
he levoﬂoxacin-based triple therapy of 10-day duration had 100%
radication in both the ITT and PP analyses.56
Finally, 5 non-randomized clinical trials evaluated the eradica-
ion rates of different second-line therapies after failed standard
larithromycin-based triple therapy with the following results: The
tandard triple therapy with metronidazole of 1-week duration had
n 88% eradication rate in the ITT analysis and a 91% eradication
ate in the PP analysis;57 with a 2-week duration the eradication
ate was 96% in the ITT analysis and 100% in the PP analysis.58 The
ffectiveness of the 2 triple therapies with levoﬂoxacin of 10-day
uration was 72.7% in both the ITT and PP analyses59 for the ﬁrst
tudy, whereas in the second study, the eradication rate was 81% in
he PP analysis and 77% in the ITT analysis.60 The sequential therapy
ith levoﬂoxacin for a duration of 10 days achieved an eradication
ate of 95.1% in the ITT analysis and 96.4% in the PP analysis.61
iscussion
he effectiveness of the different available therapeutic regimens,
oth ﬁrst-line and second-line, included in the present system-
tic review for deﬁning the ideal treatment for infection due to
. pylori varies signiﬁcantly worldwide and there is currently no
deal therapeutic strategy for eradicating H. pylori infection in 100%
f the cases. The proposal based on the standard triple therapy
as not provided satisfactory results. Its ﬁrst disadvantage is the
esistance to antimicrobial drugs, especially to clarithromycin and
etronidazole, and therefore many infected persons throughout
he world do not beneﬁt from these regimens. The sequential and
oncomitant regimens are good alternative treatments. The triple
herapy with levoﬂoxacin, as second-line treatment, is an alterna-
ive that has had excellent eradication results. Combinations that
nclude rifabutin and furazolidone are also promising therapeutic
ossibilities.
z
d
l
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Based on the observations of our review, the standard triple ther-
py as a ﬁrst-line regimen of 1-week duration shows sub-optimal
radication rates in countries such as Turkey, Colombia, Ecuador,
apan, and the United States.24,26,41,43,50 However, in other coun-
ries such as Brazil and the United Kingdom, the eradication rates
ere higher;19,51 these results were similar to those obtained in
he countries with low rates of resistance to clarithromycin (lower
han 15 to 20%). Moreover, with therapies lasting longer than
 days, greater eradication effectiveness was not found in coun-
ries that included the United States, Colombia, and Chile.24,41,42
hese results are equivalent to those observed in the meta-analysis
onducted by Fuccio et al.,62 that did not ﬁnd a higher eradica-
ion rate in therapies of more than 7-day duration; likewise, in 3
andomized clinical trials conducted by Kim et al.,63 and Zagari
t al.,64 the 2-week regimens did not have higher eradication rates
han those of 1-week duration. Therefore, our review suggests that
 duration greater than 7 days does not improve the performance
f the standard triple therapy and that the resistance to antibiotics
s the principal cause of eradication failure.18
On the other hand, the triple therapies with amoxicillin and the
riple therapies with metronidazole for 7 days were equally effec-
ive, but the H. pylori eradication rates were unacceptable.29 Even
hough the triple therapies at high and low doses of metronida-
ole are considered effective, there were no signiﬁcant differences
n their effectiveness with respect to dose.33 There were also no
ifferences in the 7-day triple therapies with clarithromycin in
elation to the PPIs employed: pantoprazole and omeprazole, lanso-
razole and omeprazole, or rabeprazole and omeprazole.24,25,45,50
he eradication rates, even though they were signiﬁcantly higher
ith the triple therapy with clarithromycin, are still poor with
espect to the dual therapy with clarithromycin, which achieved
 better, but still unacceptable rate, according to the previously
iscussed criteria.26,65 Based on the results obtained from the dif-
erent clinical trials included in this study, conducted in different
eographic zones, it is suggested that this latter therapy reaches
nacceptable eradication rates for cure (< 80%) in countries with
rowing rates of resistance to clarithromycin and metronidazole.12
evertheless, these results cannot be generalized worldwide, given
hat this therapeutic option is still adequate in countries that have
. pylori strains with a low resistance to clarithromycin (< 15-20%)
nd metronidazole (< 40%).10
In the presence of the growing increase in resistance to clar-
thromycin and the sub-optimum eradication rates offered by the
tandard triple therapy, new rescue therapies have emerged, such
s the bismuth-containing quadruple therapy. In 3 studies included
n our review, this therapy given for 7 days has obtained acceptable
ffectiveness in the ITT analyses and good effectiveness when given
or 10 or 14 days.20,23,37,39,52 Our ﬁndings are adequately correlated
ith those of a meta-analysis conducted by Fischbach et al.66 in
hich they conclude that the quadruple therapies of 2-week dura-
ion improve effectiveness in relation to those of 1-week duration.
n our review, the eradication rates of the quadruple therapy ver-
us the standard triple therapy as ﬁrst-line treatments were similar
nd there was no statistically signiﬁcant difference between these 2
herapeutic regimens of 7 or 10-day duration.19--21,23 Likewise, our
esults are equivalent to those demonstrated in 2 meta-analyses
onducted by Gene et al.,67,68 in which the quadruple therapy and
he triple therapy reached similar eradication rates in the ITT anal-
sis (79 and 80%; p = 1).21 Despite the heterogeneity of the regimens
ncluded in this review, it can be concluded that the administration
f treatments with a prolonged duration (greater than or equal to
0 days) and at high doses of bismuth would enable more effective
radication rates to be achieved.69
On the other hand, the standard triple therapy with metronida-
ole as second-line treatment, after the therapeutic failure of stan-
ard triple therapy with clarithromycin, obtained ideal eradication
evels in our review; in particular, 4 clinical trials conducted in Japan
how good eradication percentages in 5 days in the ITT analysis
 b
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and excellent ones in 7 days.32,34,58 This therapy also shows itself
to be effective as a second-line regimen at doses of metronidazole
of 500 or 750 mg/day, with good success rates in the ITT analyses for
both regimens, even reaching up to a 93.5% eradication rate.33 The
previous results could be explained by taking into account the geo-
graphic location in which the clinical experiments were carried out,
given that the resistance rates to metronidazole are low in Japan
(approximately 4%), whereas the resistance to clarithromycin is high
(approximately 27.7%); this is above the recommended resistance
limit for using clarithromycin (< 15-20%), but it is still within the
accepted resistance limit for using metronidazole (< 40%).70 Never-
theless, when the standard triple therapy with clarithromycin fails,
this antibiotic should not be included in the second-line treatment,
because its secondary resistance would increase drastically.71
In our review, as ﬁrst-line treatment the 10-day sequential ther-
apy offers superior eradication rates with excellent effectiveness in
the ITT analysis, compared with the 7-day standard triple therapy
that has shown poor effectiveness.31 The sequential therapy pro-
vides good cure rates, above 90%,13 concurring with the results of 3
clinical trials conducted in Israel, Taiwan, and Italy that are included
in the present review. It was used as ﬁrst-line therapy and reached
effective ITT eradication rates that were excellent and good in the
latter two countries, respectively.53,56,61 Similar results have been
reported in the systematic reviews carried out by Moayedi,72 Jafri
et al.,73 and Grigorios et al.74
Another effective alternative to the standard triple therapy is
concomitant or quadruple therapy without bismuth. In our review,
2 studies with concomitant therapy showed greater eradication in
the PP analyses, excellent versus acceptable compared with the
standard triple therapy.35,46 Likewise, meta-analyses conducted by
Essa et al.75 and Georgopoulos et al.,76 obtained similar results
to those of the present review.13 However, contrary to the pre-
viously obtained results, a Latin American study showed that the
14-day standard triple therapy was more effective than the 5-day
concomitant therapy or the 10-day sequential therapy, with accep-
table, unacceptable, and poor eradication rates, respectively.1,47
The discrepancies with the previous results could be explained by
geographic variations and patterns of resistance to clarithromycin.
As the authors of the Latin American study explained, the population
included in the clinical experiment had a low prevalence of clar-
ithromycin resistance and therefore achieved better results with
the standard triple therapy.47,77,78
As clarithromycin replacement, therapy with quinolones associ-
ated with amoxicillin in the regular doses and a PPI twice a day has
been suggested. In our review, the triple therapy with levoﬂoxacin
with a duration of 7 to 14 days was evaluated in 7 clinical trials and
achieved poor to excellent eradication rates in the ITT analyses;
effectiveness improved with the longer treatments.27,29,30 Addi-
tionally, as ﬁrst-line therapy, this treatment was more effective
than both the triple therapy with clarithromycin of 7-day duration
and the triple therapy with metronidazole.29 Likewise, no signif-
icant difference was found between the doses of levoﬂoxacin of
500 mg once a day versus 500 mg twice a day. Effectiveness was
unacceptable in the two cases, whereas in relation to the 10-day
sequential therapy, greater eradication rates in the PP and ITT anal-
yses were obtained, excellent versus acceptable, respectively.30,56
The above results are similar to those described by Kuo et al.,13
Molina-Infante et al.,79 and Cheng et al.80 As second-line rescue
therapy, the eradication rates varied from acceptable to excellent
with 10-day therapies,28,56,59,60 whereas they ranged from poor to
unacceptable with 7-day treatments.40,54 The least successful erad-
ication rate was obtained in a clinical trial conducted in Turkey,
and might be related to the fact that this therapy could present
success failures in Asian and European populations with a high resis-
tance to ﬂuoroquinolones, reducing their effectiveness to rates of
approximately 33%.81,82 The abovementioned studies suggest that
the triple therapy with a dose of 400 mg/day of levoﬂoxacin is less
effective compared with a therapy using 800 mg per day, whereas
o
f
c
e45
etter results could be obtained with more prolonged therapies.28
inally, it is concluded that the triple therapy with levoﬂoxacin is
n effective ﬁrst and second-line treatment that offers better erad-
cation rates in relation to the standard, quadruple, and sequential
herapies.
Other second-line rescue antibiotics such as rifabutin and fura-
olidone have been employed. In this review, we evaluated a 7-day
herapy with rifabutin associated with omeprazole and amoxicillin
nd it had a quite unacceptable effectiveness, much lower in rela-
ion to the bismuth-containing quadruple therapy that obtained
oor effectiveness in the ITT analysis.36 However, these results
an most likely be explained by the fact that a 7-day duration is
ot sufﬁcient, given that other studies have published more effec-
ive results with longer treatments; therapies of 10 and 12 days
ave offered good eradication rates and those of 7-day duration
ave shown poor rates.83 The latter result could be related to the
oses of amoxicillin and PPI employed, taking into account the
tudy conducted by Borody et al.,84 in which higher 12-day doses of
hese antibiotics were used, showing effective results as second-line
escue therapy. Nevertheless, currently there is no clear optimal
herapeutic regimen with rifabutin.13 In regard to furazolidone,
n additional antibiotic that has been used in rescue treatments
n quadruple combination (bismuth, doxycycline, PPI, and furazoli-
one), had excellent success in the ITT analysis and good success
n the triple combination (furazolidone, levoﬂoxacin, and PPI).49
pon increasing the dose of furazolidone, we observed a poor erad-
cation rate with a dose of 200 mg per day and a good rate with a
ose of 400 mg.48 The promising eradication rates of the therapy
ith furazolidone could be explained by the absence of primary
esistance to this antibiotic and the absence of crossed resistance
ith metronidazole.85 Therefore, in the underdeveloped countries
ith a high resistance to metronidazole, therapies with furazolidone
ould be effective rescue therapies.86
The eradication of H. pylori is also a challenge in patients
hat are allergic to penicillin, in both ﬁrst-line treatments and in
ases of previous therapeutic failure. In our review, therapy with
meprazole, clarithromycin, and metronidazole of 7-day duration
btained quite unacceptable effectiveness of under 70% success in
he ITT and PP analyses. On the other hand, triple therapy with lev-
ﬂoxacin, omeprazole, and clarithromycin of 10-day duration was
 good second-line strategy, with good cure rates in the ITT and PP
nalyses.55 Nevertheless, these results differ from previous studies
n which eradication success was poor with the use of PPI, clar-
thromycin, and metronidazole. Once again, these results can be
orrelated with the area in which the clinical trial was conducted,
iven that in Spain there is very high resistance to metronida-
ole and clarithromycin, of approximately 32.8% and 49.2%.87 In
ddition, different authors that have evaluated the combination of
evoﬂoxacin as second-line rescue therapy reported similar eradica-
ion rates, with excellent effectiveness in the ITT analysis.29,88 With
his in mind, our suggestion for patients with a history of allergy to
enicillin is the triple therapy with PPI, clarithromycin, and metron-
dazole; it is an adequate ﬁrst-line strategy in countries where there
s low resistance to these antibiotics. In other words, the regimens
ith levoﬂoxacin achieve good eradication rates as a second-line
lternative in this type of patient.29,58,89
In a systematic review carried out by Gisbert et al.90 that
ncluded 18 randomized clinical trials in their analysis there was
 difference that was not statistically signiﬁcant between the erad-
cation rates of the triple regimens based on nitroimidazoles and
moxicillin; these results were similar to ours. According to the
ndings of 4 systematic reviews91--93 that compared triple regimens
ith different PPIs as ﬁrst-line treatment, 3 of them did not show
 signiﬁcant difference in their eradication rates, concurring with
ur review. However, in contrast, an additional systematic review
avored the regimens based on esomeprazole.91 Our results indi-
ate that treatment duration above 7 days does not improve the
ffectiveness of the standard triple therapy, but this differs with
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he systematic review of Calvet et al.;94 they included 7 random-
zed clinical trials in their analysis and justify the use of 14-day
herapies versus 7-day therapies. Nevertheless, in these 7 stud-
es different therapeutic combinations were employed: PPI plus
moxicillin and clarithromycin, clarithromycin plus metronidazole
r amoxicillin and clarithromycin and metronidazole. Because of
he above, it is difﬁcult to compare our ﬁndings with those of that
tudy. Even so, these results would indicate that the high rates of
ntibiotic resistance in different geographic regions are the main
ause of eradication failure, more so than the length of time of
reatment.
Adamek et al., 71 support our results with a similar effectiveness
etween the triple and quadruple therapies as ﬁrst-line regimens.
his is also validated by the results obtained in the systematic
eview by Calvet et al., 94 analyzing 5 randomized clinical trials
ithout ﬁnding signiﬁcant differences in the eradication rates of
hese therapies. Likewise, the latter work indicates that the triple
herapies based on nitroimidazoles and amoxicillin show similar
radication rates for H. pylori, while the triple therapies using
ifferent PPIs show equal eradication effectiveness.71 Like ours,
 systematic review by Huang and Hunt95 reports similar eradica-
ion rates between clarithromycin at single and double doses. Two
ystematic reviews72 that include 12 clinical trials in their analysis
upport our results with respect to the use of the 10-day sequential
egimen, compared with the 7 and 10-day triple regimens as ﬁrst-
ine treatments. However, the Italian authors indicate that these
esults must be reliably corroborated by large-scale studies.
For reaching more effective eradication rates in regard to the
econd-line therapies, in their review Megraud and Marshall65 rec-
mmend not using clarithromycin in the case of therapeutic failures
f ﬁrst-line regimens based on this antibiotic, and suggest doubling
he dose of metronidazole in the case of a previous eradication
ailure with that drug; they also state that second-line treatment
hould be given for a longer period of time than ﬁrst-line treatment.
ven though we did not ﬁnd systematic reviews that compared
he quadruple versus the triple regimens as second-line regimens,
here is a current controversy as to which regimen is more effec-
ive, according to the results of 3 randomized clinical trials by
ee et al.,96 Magaret et al.,97 and Peitz et al.98 The results of 2
arge meta-analyses 99,100 similarly corroborate that the triple ther-
py with levoﬂoxacin is capable of reaching eradication rates even
igher than the quadruple therapy in those patients that have had
rst-line standard triple therapy failure.
A limitation of the present systemic review, now proposed for
 future study, was not having incorporated the antimicrobial sus-
eptibility of the different therapeutic regimens into the search
arameters; doing so would have addressed the important problem
f resistance that does not allow for eradication rates above 95% to
e obtained. Likewise, given today’s complex regimens, treatment
dherence, safety, and adverse effects, as well as the cost-beneﬁt
valuation of therapeutic interventions should all be taken into
onsideration, enabling an overall approximation in the evaluation
f the ideal H. pylori treatment. On the other hand, because of
he high clinical heterogeneity (populations, interventions, study
urations and designs) of the clinical trials evaluating the effec-
iveness of both ﬁrst and second-line therapies, future systematic
eviews should be carried out. This type of epidemiologic design is
hought to be the most appropriate today for elaborating the solid
nowledge that can provide the medical community with the most
dequate competencies for the ideal management of this infection.
he inclusion of clinical trials at the worldwide level makes this a
omprehensive work in which it is possible to have representative
esults in different patient populations.onclusions
nfection from Helicobacter pylori should be treated as any other
nfectious disease, which is why a therapy must be capable of curingF.  Sierra  et  al.
ore than 95% of the cases in the ﬁrst therapeutic attempt in order
o be regarded as excellent.6 The effectiveness of the different
vailable treatment strategies varies signiﬁcantly within different
eographic regions. Such is the case with the standard triple ther-
py, which continues to be ineffective in countries with strains
hat are resistant, mainly to agents such as clarithromycin and
etronidazole, making this treatment unacceptable as empirical
herapy. Among the ﬁrst-line treatment options is the bismuth-
ased quadruple therapy, which did not show signiﬁcant differences
n its eradication rates versus those of the standard triple therapy.
owever, the sequential and concomitant therapies have superior
radication results, with the potential to improve their effective-
ess through increasing treatment duration, whereas the triple
herapy with levoﬂoxacin offers the best results as ﬁrst and second-
ine treatment. With this in mind, a 10-day sequential treatment
ould be used as ﬁrst-line treatment and a 10-day levoﬂoxacin-
ased regimen as retreatment. As a second-line regimen it should
e administered for a longer period of time than the ﬁrst-line
reatment; if there is initial failure with the clarithromycin-based
egimen, this antibiotic should not be used again. On the contrary,
f there is initial failure with metronidazole, increased dose and
reatment duration with this same drug is recommended as rescue
reatment.
The order of choice of the different H. pylori eradicating regi-
ens will depend on local studies in which the rates of resistance
o the different antibiotics are determined, in order to give the
ppropriate initial treatment, ruling out the less effective thera-
ies according to the experiences of each country.70 However, we
onsider that antimicrobial sensitivity should not be systematically
valuated after a ﬁrst therapeutic failure so that effective eradica-
ion results can be achieved. 65,101
It is imperative to carry out a greater number of large-scale stud-
es and of double-blind, randomized clinical trials with excellent
ethodological quality that compare current standard treatments
ith new therapies, so that the ideal therapeutic regimen can be
stablished. The success rate of such beneﬁcial treatment should
e as close to 100% as possible.102
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